ClearTrial announced the launch of ClearTrial 4.2, a release that introduces the ClearTrial Web Services API (Application Programming Interface). The ClearTrial Web Services API streamlines the integration of ClearTrial with any system that can utilize a Web Service.
"Our customers increasingly rely on ClearTrial software as a unifying platform and system of record for the planning, forecasting, and tracking of clinical projects, which requires the seamless flow of information between many other systems," noted Andrew Grygiel, Vice President of Marketing and Product Management for ClearTrial. "The new Web Services APIaims to makes the integration and interoperability of ClearTrial with their existing systems even faster and easier than before."
As one example, the ClearTrial Web Services API can be used to automate the flow of data between ClearTrial software and a resource management system such as Planisware or Primavera. This allows the resource management system, in assigning named resources to projects, to utilize the ClearTrial activity-based resource demand forecast.
ClearTrial 4.2 also delivers several features that provide flexibility and configurability in study planning, forecasting, outsourcing, and tracking. In addition, the new release offers expanded clinical intelligence and refined cost drivers.
The major new features of ClearTrial 4.2 include:
Meetings Manager – ClearTrial Meetings Manager provides a single interface to efficiently manage and track all required meetings through the life of a study. Users can create both recurring and one-off meetings of various types; choose the meeting attendees for each meeting and enter specific meeting details such as meeting attendance method and preparation time; track and override pass-through costs associated with meetings; and automatically generate new reports of meeting-related assumptions, labor fees and pass-through costs.
EDC Maturity Model – ClearTrial software has been enhanced to more accurately calculate Electronic Data Capture (EDC) labor fees and pass-through costs by leveraging a configurable EDC Maturity Model. This enhancement is based on industry research into the differing stages of EDC deployment in the industry, ranging from limited deployment and experience with EDC, to complete enterprise deployment of EDC.
Reporting Regions – ClearTrial 4.2 further advances the configurability of the software to reflect business processes by enabling the creation of user-defined regions for reporting purposes. An organization can map countries to reporting regions and use this grouping to roll-up labor fees and costs in financial reports such as the Monthly Budget.
Expanded industry intelligence – ClearTrial 4.2 has been enhanced to support 47 new indications across several therapeutic areas. ClearTrial now supports more than 200 therapeutic indications, with algorithms derived from a careful analysis of the cost and time drivers that affect each study task specifically for that indication.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.